EKSO - Ekso Bionics Holdings Inc
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
18%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -19.32%
Operating Income is Negative
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -77.2%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 2.38
Debt Ratio is 0.53
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Ekso Bionics Holdings Inc (EKSO) - https://ir.eksobionics.com/
since 2005, ekso bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. the company’s first commercially available product called ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. by designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, ekso bionics is helping people rethink current physical limitations and achieve the remarkable. ekso bionics is headquartered in richmond, california international offices: europe/middle east/africa 29th floor one canada square canary wharf london, united kingdom +44 20 7060 3568 kunden service deutschland +49 89 55067774Exchange - NASDAQ
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO - Jack Peurach
Employees - 116
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.